Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 2
1998 3
2000 1
2001 3
2002 4
2003 1
2004 2
2005 1
2006 3
2007 1
2008 4
2009 2
2010 5
2011 6
2012 3
2013 1
2018 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

42 results
Results by year
Filters applied: . Clear all
Page 1
High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study.
Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, Bell H, Gangsøy-Kristiansen M, Matre J, Rydning A, Wikman O, Danielsson A, Sandberg-Gertzén H, Ung KA, Eriksson A, Lööf L, Prytz H, Marschall HU, Broomé U. Olsson R, et al. Gastroenterology. 2005 Nov;129(5):1464-72. doi: 10.1053/j.gastro.2005.08.017. Gastroenterology. 2005. PMID: 16285948 Clinical Trial.
This study aimed at studying the effect of a higher dose of ursodeoxycholic acid than previously used on survival, symptoms, biochemistry, and quality of life in this disease. ...Analyses of serum ursodeoxycholic acid concentration gave no evide …
This study aimed at studying the effect of a higher dose of ursodeoxycholic acid than previously used on survival, symp …
High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective.
Cullen SN, Rust C, Fleming K, Edwards C, Beuers U, Chapman RW. Cullen SN, et al. J Hepatol. 2008 May;48(5):792-800. doi: 10.1016/j.jhep.2007.12.023. Epub 2008 Feb 14. J Hepatol. 2008. PMID: 18314215 Clinical Trial.
BACKGROUND/AIMS: Ursodeoxycholic acid (UDCA) has been shown to improve serum liver tests in primary sclerosing cholangitis (PSC), but controlled trials have shown inconsistent effects on liver histology, and did not reveal a survival benefit. ...METHODS: Thirty-one …
BACKGROUND/AIMS: Ursodeoxycholic acid (UDCA) has been shown to improve serum liver tests in primary sclerosing cholangitis (PS …
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
Smith T, Befeler AS. Smith T, et al. Curr Gastroenterol Rep. 2007 Mar;9(1):54-9. doi: 10.1007/s11894-008-0021-z. Curr Gastroenterol Rep. 2007. PMID: 17335678 Review.
Ursodeoxycholic acid (UDCA), a hydrophilic bile acid, is the most promising treatment option because of its benign side effect profile and documented benefit in the treatment of other cholestatic liver diseases, including primary biliary cirrhosis. Multiple s
Ursodeoxycholic acid (UDCA), a hydrophilic bile acid, is the most promising treatment option because of its benign side
High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater?
Chapman RW. Chapman RW. Hepatology. 2009 Sep;50(3):671-3. doi: 10.1002/hep.23174. Hepatology. 2009. PMID: 19714717 No abstract available.
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Mooney J, Sargeant C, Braaten J, Bernard T, King D, Miceli E, Schmoll J, Hoskin T, Thapa P, Enders F. Lindor KD, et al. Hepatology. 2009 Sep;50(3):808-14. doi: 10.1002/hep.23082. Hepatology. 2009. PMID: 19585548 Free PMC article. Clinical Trial.
Previous controlled trials are inconclusive regarding the efficacy of ursodeoxycholic acid (UDCA) for treating primary sclerosing cholangitis (PSC). One hundred fifty adult patients with PSC were enrolled in a long-term, randomized, double-blind controlled trial of …
Previous controlled trials are inconclusive regarding the efficacy of ursodeoxycholic acid (UDCA) for treating primary scleros …
High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.
Eaton JE, Silveira MG, Pardi DS, Sinakos E, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Lindor KD. Eaton JE, et al. Am J Gastroenterol. 2011 Sep;106(9):1638-45. doi: 10.1038/ajg.2011.156. Epub 2011 May 10. Am J Gastroenterol. 2011. PMID: 21556038 Free PMC article. Clinical Trial.
OBJECTIVES: Some studies have suggested that ursodeoxycholic acid (UDCA) may have a chemopreventive effect on the development of colorectal neoplasia in patients with ulcerative colitis (UC) and primary sclerosing cholangitis (PSC). We examined the effects of hig
OBJECTIVES: Some studies have suggested that ursodeoxycholic acid (UDCA) may have a chemopreventive effect on the development …
Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression.
Sinakos E, Marschall HU, Kowdley KV, Befeler A, Keach J, Lindor K. Sinakos E, et al. Hepatology. 2010 Jul;52(1):197-203. doi: 10.1002/hep.23631. Hepatology. 2010. PMID: 20564380 Free PMC article.
High-dose (28-30 mg/kg/day) ursodeoxycholic acid (UDCA) treatment improves serum liver tests in patients with primary sclerosing cholangitis (PSC) but does not improve survival and is associated with increased rates of serious adverse events. ...CONCLU
High-dose (28-30 mg/kg/day) ursodeoxycholic acid (UDCA) treatment improves serum liver tests in patients with pr
High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia.
Lindström L, Boberg KM, Wikman O, Friis-Liby I, Hultcrantz R, Prytz H, Sandberg-Gertzén H, Sangfelt P, Rydning A, Folvik G, Gangsøy-Kristiansen M, Danielsson A, Bergquist A. Lindström L, et al. Aliment Pharmacol Ther. 2012 Feb;35(4):451-7. doi: 10.1111/j.1365-2036.2011.04966.x. Epub 2012 Jan 5. Aliment Pharmacol Ther. 2012. PMID: 22221173 Free article. Clinical Trial.
AIM: To evaluate the effect of high dose (17-23 mg/kg/day) UDCA on colorectal neoplasia in a cohort of patients with PSC and IBD. ...CONCLUSIONS: Long-term high dose ursodeoxycholic acid does not prevent colorectal cancer or dysplasia in …
AIM: To evaluate the effect of high dose (17-23 mg/kg/day) UDCA on colorectal neoplasia in a cohort of patients with PSC and I …
High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis.
Harnois DM, Angulo P, Jorgensen RA, Larusso NF, Lindor KD. Harnois DM, et al. Am J Gastroenterol. 2001 May;96(5):1558-62. doi: 10.1111/j.1572-0241.2001.03777.x. Am J Gastroenterol. 2001. PMID: 11374699 Clinical Trial.
OBJECTIVES: To assess the tolerability and efficacy of high-dose (25-30 mg/kg per day) ursodeoxycholic acid (UDCA) in patients with primary sclerosing cholangitis (PSC). ...High-dose UDCA was well tolerated. CONCLUSIONS: UDCA at a dose
OBJECTIVES: To assess the tolerability and efficacy of high-dose (25-30 mg/kg per day) ursodeoxycholic acid (UDC …
Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up.
van de Meeberg PC, Houwen RH, Sinaasappel M, Heijerman HG, Bijleveld CM, Vanberge-Henegouwen GP. van de Meeberg PC, et al. Scand J Gastroenterol. 1997 Apr;32(4):369-73. doi: 10.3109/00365529709007686. Scand J Gastroenterol. 1997. PMID: 9140160 Clinical Trial.
BACKGROUND: Ursodeoxycholic acid (UDCA) is beneficial in cholestasis related to cystic fibrosis (CF). High-dose treatment has been recommended to compensate for bile salt malabsorption. ...Complete normalization of liver enzymes and bilirubin occurred …
BACKGROUND: Ursodeoxycholic acid (UDCA) is beneficial in cholestasis related to cystic fibrosis (CF). High-dose
42 results
Jump to page
Feedback